- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07867327
A Study of LY4515100 in Healthy Male Participants
A Phase 1, Open-Label, 2-Part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [¹⁴C]-LY4515100 in Healthy Male Participants
The main purpose of this study is to evaluate how the body handles [¹⁴C]-LY4515100. The study will investigate how much [¹⁴C]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes [¹⁴C]-LY4515100 so that it can be used or removed, and how the body gets rid of [¹⁴C]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-post: LillyTrials@Lilly.com
Studer Kontakt Backup
- Navn: Physicians interested in becoming principal investigators please contact
- E-post: clinical_inquiry_hub@lilly.com
Studiesteder
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53704
- Rekruttering
- Fortrea Clinical Research Unit
-
Hovedetterforsker:
- Kimberly Cruz
-
Ta kontakt med:
- Telefonnummer: 608-442-8200
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Are overtly healthy as determined by medical evaluation.
- Have a body mass index (BMI) within the range of 18.0 to 35.0 kilograms per square meter (kg/m²), inclusive.
Exclusion Criteria:
- Have significant previous or current history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinal, hematological, neurological, thromboembolism, or bleeding disorder capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study intervention; or of interfering with the interpretation of data.
- Have a significant history of or current psychiatric disorders.
- Have history of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs. Uncomplicated appendectomy and hernia repair will be allowed.
- Have a history of constipation or have had acute constipation within 3 weeks prior to check-in.
- Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing, for example, serial x-ray or computed tomography scans, barium meal, or current employment in a job requiring radiation exposure monitoring.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: [¹⁴C]-LY4515100 Part 1
[¹⁴C]-LY4515100 containing radioactivity administered orally |
[¹⁴C]-LY4515100 administered orally |
|
Eksperimentell: LY4515100 + [¹⁴C]-LY4515100 Part 2
LY4515100 administered orally with [¹⁴C]-LY4515100 containing radioactivity administered intravenously (IV) |
LY4515100 administered orally [¹⁴C]-LY4515100 administered IV |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Part 1: Urinary Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Tidsramme: Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 1: Fecal Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Tidsramme: Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 2: Dose Normalized Ratio of the Area Under the Concentration-Time Curve After Oral Administration (AUCpo) to Area Under the Concentration-Time Curve After Intravenous Administration (AUCiv) of LY4515100
Tidsramme: Predose Up to Day 14
|
Predose Up to Day 14
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Part 1: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity
Tidsramme: Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 1: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity
Tidsramme: Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 1: Total Radioactivity Recovered in Urine, Feces, and Expired Air
Tidsramme: Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 1: Total Number of Metabolites of LY4515100 in Urine, Feces, and Plasma
Tidsramme: Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 2: PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of [¹⁴C]-LY4515100
Tidsramme: Predose Up to Day 9
|
Predose Up to Day 9
|
|
Part 2: PK: Maximum Concentration (Cmax) of [¹⁴C]-LY4515100
Tidsramme: Predose Up to Day 9
|
Predose Up to Day 9
|
|
Part 2: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity
Tidsramme: Predose Up to Day 9
|
Predose Up to Day 9
|
|
Part 2: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity
Tidsramme: Predose Up to Day 9
|
Predose Up to Day 9
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 27791
- J6V-MC-OIAC (Annen identifikator: Eli Lilly and Company)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .